drugset / Trial / NCT00728936
Placebo-controlled, Dose-escalation Study of the Safety of IMO-2125 (Immunomodulatory Oligonucleotide) in Hepatitis C-infected Patients
RandomizedParallel-groupQuadruple-blindTreatment
Summary
First-in-humans, phase 1, dose-escalation study with 4 dose levels of single-agent IMO-2125.
Timeline
- Start
- 2007-09
- Primary completion
- 2009-12
- Completion
- 2010-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tilsotolimod | Unknown | 0.04 mg/kg | — |
| Subject | Tilsotolimod | Unknown | 0.08 mg/kg | — |
| Subject | Tilsotolimod | Unknown | 0.16 mg/kg | — |
| Subject | Tilsotolimod | Unknown | 0.32 mg/kg | — |
| Subject | Tilsotolimod | Unknown | 0.48 mg/kg | — |